Drug Trial Radar · NCT07886554
LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH)
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Dec 2028
Study completion Jun 2029
Sponsor
- Lead sponsor
- IRulya Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 (Inhaled Sirolimus) in Adults with Sarcoidosis Associated Pulmonary Hypertension (SAPH)
Conditions
- Sarcoidosis Associated Pulmonary Hypertension
Interventions
PlaceboDrug
Matching placebo administered via dry powder inhalation
LAM-001Drug
LAM-001 administered via dry powder inhaler
LAM-001Drug
LAM-001 administered via dry powder inhaler
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Pulmonary Vascular Resistance (PVR) at 24 weeksTime frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Temple University
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.